Francisella tularensis (Ft) is a gram-negative intercellular pathogen and category A biothreat agent. However, despite 15 years of strong government investment and intense research focused on the development of a US Food and Drug Administration-approved vaccine against Ft, the primary goal remains elusive. This article reviews research efforts focused on developing an Ft vaccine, as well as a number of important factors, some only recently recognized as such, which can significantly impact the development and evaluation of Ft vaccine efficacy. Finally, an assessment is provided as to whether a US Food and Drug Administration-approved Ft vaccine is likely to be forthcoming and the potential means by which this might be achieved.
CITATION STYLE
Sunagar, R., Kumar, S., Franz, B., & Gosselin, E. (2016). Tularemia vaccine development: paralysis or progress? Vaccine: Development and Therapy, 9. https://doi.org/10.2147/vdt.s85545
Mendeley helps you to discover research relevant for your work.